Gene therapy injection aims to slow vision loss from dry AMD

NCT ID NCT06765980

Recruiting now Disease control Sponsor: Kriya Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This study tests a new gene therapy (VV-14295) given as an injection into the eye for people with geographic atrophy, a form of advanced dry age-related macular degeneration that causes blind spots. The goal is to see if it is safe and can slow the growth of these blind spots. About 62 adults aged 55 to 80 will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Kriya Clinical Study Site
RECRUITING

Erie, Pennsylvania, 16505, United States

Contact Email: •••••@•••••
Kriya Clinical Study Site
RECRUITING

Ottawa, Ontario, Canada

Contact Email: •••••@•••••
Kriya Clinical Study Site
RECRUITING

Tel Aviv, Israel

Contact Email: •••••@•••••
Kriya Clinical Study Site
RECRUITING

Christchurch, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.